Unity Biotechnology found using ticker (UBX) have now 7 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 12 and 3 calculating the average target price we see 6.86. Given that the stocks previous close was at 0.7 this would imply there is a potential upside of 880.0%. The 50 day MA is 0.9 and the 200 day moving average is 1.66. The market capitalisation for the company is $47m. You can visit the company’s website by visiting: https://unitybiotechnology.com
The potential market cap would be $461m based on the market concensus.
Unity Biotechnology, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company’s lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge and changed its name to Unity Biotechnology in January 2015. Unity Biotechnology was incorporated in 2009 and is headquartered in South San Francisco, California.
